Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aethlon Medical, Inc. stock logo
AEMD
Aethlon Medical
$1.50
-1.8%
$1.65
$1.35
$5.00
$3.94M1.888,433 shs256 shs
Bluejay Diagnostics, Inc. stock logo
BJDX
Bluejay Diagnostics
$0.58
+5.3%
$0.75
$0.47
$13.98
$1.56M0.8545,634 shs15,571 shs
Cabot Oil & Gas Co. stock logo
COG
Cabot Oil & Gas
$17.89
$14.28
$23.10
$8.89B0.158.21 million shs1.24 million shs
Khiron Life Sciences Corp. stock logo
KHRN
Khiron Life Sciences
C$0.04
C$0.04
C$0.04
C$0.21
C$9.30M2.64256,268 shs24,000 shs
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
$0.46
+7.8%
$0.41
$0.28
$2.42
$8.83M1.88346,247 shs24,274 shs
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aethlon Medical, Inc. stock logo
AEMD
Aethlon Medical
+1.20%+6.99%-12.07%-20.30%-66.00%
Bluejay Diagnostics, Inc. stock logo
BJDX
Bluejay Diagnostics
-12.02%-0.02%-32.94%-28.77%-91.35%
Cabot Oil & Gas Co. stock logo
COG
Cabot Oil & Gas
0.00%0.00%0.00%0.00%0.00%
Khiron Life Sciences Corp. stock logo
KHRN
Khiron Life Sciences
0.00%0.00%0.00%0.00%-6.98%
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
-1.35%-5.51%-7.57%+0.02%-56.16%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aethlon Medical, Inc. stock logo
AEMD
Aethlon Medical
1.3106 of 5 stars
3.53.00.00.01.10.00.6
Bluejay Diagnostics, Inc. stock logo
BJDX
Bluejay Diagnostics
N/AN/AN/AN/AN/AN/AN/AN/A
Cabot Oil & Gas Co. stock logo
COG
Cabot Oil & Gas
0.7828 of 5 stars
0.00.01.70.00.60.03.8
Khiron Life Sciences Corp. stock logo
KHRN
Khiron Life Sciences
N/AN/AN/AN/AN/AN/AN/AN/A
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aethlon Medical, Inc. stock logo
AEMD
Aethlon Medical
3.00
Buy$10.00565.87% Upside
Bluejay Diagnostics, Inc. stock logo
BJDX
Bluejay Diagnostics
2.00
HoldN/AN/A
Cabot Oil & Gas Co. stock logo
COG
Cabot Oil & Gas
N/AN/AN/AN/A
Khiron Life Sciences Corp. stock logo
KHRN
Khiron Life Sciences
N/AN/AN/AN/A
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
N/AN/AN/AN/A

Current Analyst Ratings

Latest BJDX, AEMD, KHRN, VIRI, and COG Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/4/2024
Aethlon Medical, Inc. stock logo
AEMD
Aethlon Medical
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$23.00 ➝ $10.00
(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aethlon Medical, Inc. stock logo
AEMD
Aethlon Medical
$570K6.90N/AN/A$6.56 per share0.23
Bluejay Diagnostics, Inc. stock logo
BJDX
Bluejay Diagnostics
$250K6.23N/AN/A$2.34 per share0.25
Cabot Oil & Gas Co. stock logo
COG
Cabot Oil & Gas
$1.47B0.00N/A12.93$5.56 per share0.00
Khiron Life Sciences Corp. stock logo
KHRN
Khiron Life Sciences
C$16.14M0.58C$0.01 per share6.67C$0.12 per share0.33
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
N/AN/AN/AN/A$0.20 per shareN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aethlon Medical, Inc. stock logo
AEMD
Aethlon Medical
-$12.03M-$4.99N/AN/AN/AN/A-106.28%-86.60%6/26/2024 (Estimated)
Bluejay Diagnostics, Inc. stock logo
BJDX
Bluejay Diagnostics
-$9.95M-$9.01N/AN/AN/A-168.38%-122.58%5/8/2024 (Estimated)
Cabot Oil & Gas Co. stock logo
COG
Cabot Oil & Gas
$200.53M$0.4328.900.000.1919.77%16.52%8.16%N/A
Khiron Life Sciences Corp. stock logo
KHRN
Khiron Life Sciences
-C$30.66M-C$0.17N/AN/A-190.00%-74.68%-20.79%N/A
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
-$5.30M-$0.28N/AN/AN/AN/A-110.15%-100.18%5/9/2024 (Estimated)

Latest BJDX, AEMD, KHRN, VIRI, and COG Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/28/2024Q4 2023
Bluejay Diagnostics, Inc. stock logo
BJDX
Bluejay Diagnostics
-$0.68-$1.78-$1.10-$1.78N/AN/A
2/29/2024Q4 2023
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
-$0.09-$0.06+$0.03-$0.06N/AN/A
2/14/2024Q3 2024
Aethlon Medical, Inc. stock logo
AEMD
Aethlon Medical
-$1.23-$1.37-$0.14-$1.37N/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aethlon Medical, Inc. stock logo
AEMD
Aethlon Medical
N/AN/AN/AN/AN/A
Bluejay Diagnostics, Inc. stock logo
BJDX
Bluejay Diagnostics
N/AN/AN/AN/AN/A
Cabot Oil & Gas Co. stock logo
COG
Cabot Oil & Gas
$0.44N/AN/A102.33%N/A
Khiron Life Sciences Corp. stock logo
KHRN
Khiron Life Sciences
N/AN/AN/AN/AN/A
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aethlon Medical, Inc. stock logo
AEMD
Aethlon Medical
N/A
3.93
3.93
Bluejay Diagnostics, Inc. stock logo
BJDX
Bluejay Diagnostics
N/A
1.82
1.82
Cabot Oil & Gas Co. stock logo
COG
Cabot Oil & Gas
0.41
1.05
1.00
Khiron Life Sciences Corp. stock logo
KHRN
Khiron Life Sciences
9.46
2.02
0.72
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
N/A
11.60
11.60

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Aethlon Medical, Inc. stock logo
AEMD
Aethlon Medical
1.99%
Bluejay Diagnostics, Inc. stock logo
BJDX
Bluejay Diagnostics
18.47%
Cabot Oil & Gas Co. stock logo
COG
Cabot Oil & Gas
N/A
Khiron Life Sciences Corp. stock logo
KHRN
Khiron Life Sciences
0.22%
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
9.05%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Aethlon Medical, Inc. stock logo
AEMD
Aethlon Medical
152.62 million2.52 millionNo Data
Bluejay Diagnostics, Inc. stock logo
BJDX
Bluejay Diagnostics
102.69 million1.43 millionNot Optionable
Cabot Oil & Gas Co. stock logo
COG
Cabot Oil & Gas
503399.66 millionN/AOptionable
Khiron Life Sciences Corp. stock logo
KHRN
Khiron Life Sciences
N/A232.41 millionN/ANot Optionable
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
419.26 million17.01 millionOptionable

BJDX, AEMD, KHRN, VIRI, and COG Headlines

SourceHeadline
Virios Therapeutics, Inc. (VIRI)Virios Therapeutics, Inc. (VIRI)
finance.yahoo.com - April 14 at 7:23 PM
Virios Therapeutics seeks global patent for antiviral comboVirios Therapeutics seeks global patent for antiviral combo
investing.com - March 28 at 11:45 PM
Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVIDVirios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVID
globenewswire.com - March 26 at 9:15 AM
Virios Therapeutics announces salary cuts for employees and boardVirios Therapeutics announces salary cuts for employees and board
investing.com - February 29 at 5:35 PM
Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial ResultsVirios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results
markets.businessinsider.com - February 29 at 12:35 PM
Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial ResultsVirios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results
globenewswire.com - February 29 at 9:15 AM
Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming MilestonesVirios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming Milestones
markets.businessinsider.com - February 28 at 11:24 AM
Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming MilestonesVirios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming Milestones
globenewswire.com - February 28 at 9:15 AM
Virios Therapeutics Llc (VIRI)Virios Therapeutics Llc (VIRI)
investing.com - February 27 at 7:37 AM
Virios Therapeutics (VIRI) Price Target Increased by 14.29% to 4.08Virios Therapeutics (VIRI) Price Target Increased by 14.29% to 4.08
msn.com - February 25 at 12:10 AM
Virios Therapeutics Inc Ordinary Shares VIRIVirios Therapeutics Inc Ordinary Shares VIRI
morningstar.com - February 9 at 12:13 AM
VIRI: Moving IMC-2 into Phase 2 Program in Long COVIDVIRI: Moving IMC-2 into Phase 2 Program in Long COVID
finance.yahoo.com - February 7 at 1:09 PM
Fibromyalgia Treatment Market revenue to cross USD 536 Million by 2033, says Research NesterFibromyalgia Treatment Market revenue to cross USD 536 Million by 2033, says Research Nester
finance.yahoo.com - February 6 at 3:37 PM
Virios Therapeutics Stock (NASDAQ:VIRI) Dividends: History, Yield and DatesVirios Therapeutics Stock (NASDAQ:VIRI) Dividends: History, Yield and Dates
benzinga.com - January 23 at 10:37 PM
Virios Therapeutics to advance development of IMC-2 as treatment for symptoms associated with long-CovidVirios Therapeutics to advance development of IMC-2 as treatment for symptoms associated with long-Covid
pharmabiz.com - January 23 at 7:35 AM
Virios Therapeutics Announces Plans to Advance Development of IMC-2 as Treatment for Symptoms Associated with Long-COVIDVirios Therapeutics Announces Plans to Advance Development of IMC-2 as Treatment for Symptoms Associated with Long-COVID
finanznachrichten.de - January 22 at 3:19 PM
Virios Therapeutics Announces Plans to Advance Development of IMC-2 as Treatment for Symptoms Associated with Long-COVIDVirios Therapeutics Announces Plans to Advance Development of IMC-2 as Treatment for Symptoms Associated with Long-COVID
finance.yahoo.com - January 22 at 10:18 AM
Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development ...Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development ...
bakersfield.com - January 2 at 9:21 AM
Virios Therapeutics Reports Receipt Of FDAs Feedback On Requirements For Advancing IMC-2Virios Therapeutics Reports Receipt Of FDA's Feedback On Requirements For Advancing IMC-2
markets.businessinsider.com - January 2 at 9:21 AM
Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVIDVirios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVID
finance.yahoo.com - January 2 at 9:21 AM
Taking a Closer Look At Virios Therapeutics Inc (VIRI) Following Its Recent TradeTaking a Closer Look At Virios Therapeutics Inc (VIRI) Following Its Recent Trade
knoxdaily.com - January 1 at 8:34 AM
Virios Therapeutics Inc Ordinary SharesVirios Therapeutics Inc Ordinary Shares
morningstar.com - December 7 at 10:47 PM
Virios Therapeutics, Inc. (NASDAQ:VIRI) Q3 2023 Earnings Call TranscriptVirios Therapeutics, Inc. (NASDAQ:VIRI) Q3 2023 Earnings Call Transcript
finance.yahoo.com - November 14 at 1:38 PM
VIRI: Provides Overview of Phase 3 Program in FibromyalgiaVIRI: Provides Overview of Phase 3 Program in Fibromyalgia
finance.yahoo.com - November 13 at 3:00 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Aethlon Medical logo

Aethlon Medical

NASDAQ:AEMD
Aethlon Medical, Inc., a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation. The company was incorporated in 1999 and is based in San Diego, California.
Bluejay Diagnostics logo

Bluejay Diagnostics

NASDAQ:BJDX
Bluejay Diagnostics, Inc., a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, it develops IL-6 for the monitoring of disease progression in critical care; as well as hsTNT/I and NT-proBNP for the monitoring of patients acuity with chest pain. The company was incorporated in 2015 and is headquartered in Acton, Massachusetts.
Cabot Oil & Gas logo

Cabot Oil & Gas

NYSE:COG
Cabot Oil & Gas Corp. engages in the development, exploitation, production and exploration of oil and natural gas properties. It operates through the Marcellus shale in Pennsylvania. The company was founded in 1989 and is headquartered in Houston, TX.
Khiron Life Sciences logo

Khiron Life Sciences

CVE:KHRN
Khiron Life Sciences Corp. operates as an integrated medical and cannabis company in Latin America and Europe. It operates through Health Services, Medical Cannabis Products, and Wellbeing Products segments. The company focuses on the cultivation, production, distribution, and export of tetrahydrocannabinol and cannabidiol (CBD) medical cannabis. It also operates a network of health centers and satellite clinics under the ILANS and Zerenia brands; develops CBD-based cosmeceutical products under the Kuida brand name; and operates Zerenia clinic in Medellin and Peru. Khiron Life Sciences Corp. was incorporated in 2012 and is headquartered in Vancouver, Canada.
Virios Therapeutics logo

Virios Therapeutics

NASDAQ:VIRI
Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, Inc. in July 2020. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.